Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

In vitro study of encapsulation therapy for Fabry disease using genetically engineered CHO cell line.

Y Naganawa1, K Ohsugi, R Kase

  • 1Department of Inherited Metabolic Disease, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Kodiara, Tokyo, Japan.

Cell Transplantation
|August 7, 2002
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Detailed Arterial Anatomy and Its Anastomoses of the Sphenoid Ridge and Olfactory Groove Meningiomas with Special Reference to the Recurrent Branches from the Ophthalmic Artery.

AJNR. American journal of neuroradiology·2020
Same author

Visualization of Aneurysmal Neck and Dome after Coiling with 3D Multifusion Imaging of Silent MRA and FSE-MR Cisternography.

AJNR. American journal of neuroradiology·2019
Same author

Fibroblast growth factor 13 regulates glioma cell invasion and is important for bevacizumab-induced glioma invasion.

Oncogene·2017
Same author

Late onset variants in Fabry disease: Results in high risk population screenings in Argentina.

Molecular genetics and metabolism reports·2016
Same author

Measurement and comparison of individual external doses of high-school students living in Japan, France, Poland and Belarus-the 'D-shuttle' project.

Journal of radiological protection : official journal of the Society for Radiological Protection·2015
Same author

Integrin antagonist augments the therapeutic effect of adenovirus-mediated REIC/Dkk-3 gene therapy for malignant glioma.

Gene therapy·2014

Polymer encapsulated cells secreting alpha-galactosidase A offer a novel treatment for Fabry disease. This approach reduces ceramide trihexoside accumulation, potentially avoiding lifelong enzyme replacement therapy.

Area of Science:

  • Biochemistry
  • Genetics
  • Cell Biology

Background:

  • Fabry disease is an X-linked disorder caused by alpha-galactosidase A deficiency, leading to ceramide trihexoside deposition.
  • Current enzyme replacement therapy requires lifelong intravenous administration of purified alpha-galactosidase A.
  • This necessitates a more sustainable and effective therapeutic strategy for Fabry disease.

Purpose of the Study:

  • To evaluate polymer encapsulated Chinese hamster ovary (CHO) cells engineered to secrete alpha-galactosidase A as a novel treatment for Fabry disease.
  • To assess the efficacy of secreted alpha-galactosidase A in reducing ceramide trihexoside accumulation in vitro.
  • To determine the potential of this cell encapsulation approach for in vivo therapeutic applications.

Main Methods:

Related Experiment Videos

  • Genetically modified Chinese hamster ovary (CHO) cells secreting high levels of alpha-galactosidase A were encapsulated in a semipermeable polymer.
  • A coculture system with Fabry fibroblasts was used to evaluate the uptake and efficacy of the secreted enzyme.
  • In vitro studies assessed the reduction of ceramide trihexoside accumulation in Fabry fibroblasts.

    • Main Results:

    • Encapsulated CHO cells successfully secreted functional alpha-galactosidase A through the polymeric membrane.
    • The secreted enzyme was taken up by Fabry fibroblasts, leading to a significant reduction in ceramide trihexoside accumulation.
    • In vitro results demonstrated the potential of this approach for treating Fabry disease in vivo.

    Conclusions:

    • Polymer encapsulation of alpha-galactosidase A-secreting cells presents a promising novel therapeutic strategy for Fabry disease.
    • This method may overcome limitations of current enzyme replacement therapy, offering a potentially more sustainable treatment.
    • The technology shows potential for treating Fabry disease and other lysosomal storage disorders, with the semipermeable membrane offering protection against immune rejection.